There isn't a day that goes by on Wall Street when certain stocks trading for under $10 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and sod risk management are banking ridiculous coin on a regular basis.

Just take a look at some of the big movers to the upside in the under-$10 complex from Wednesday, including Rennova (RNVA) , which soared by 38.3%; Anthera Pharmaceuticals (ANTH) , which ripped higher by 38.1%; Intrepid Potash (IPI - Get Report) , which jumped by 36.8%; and BioPharmX (BPMX - Get Report) , which surged by 29.3%. You don't even have to catch the entire move in lower-priced stocks such as these to make outsized returns when trading.

Low-priced stocks are something that I tweet about on a regular basis. These are also the exact type of stocks that I love to trade and alert in real time. I frequently flag high-probability setups, breakout candidates and low-priced stocks that are acting technically bullish. I like to hunt for low-priced stocks that are showing bullish price and volume trends, since that increases the probability of those stocks heading higher. These setups often produce monster moves higher in very short time frames.

When I trade under-$10 stocks, I do it almost entirely based off of the charts and technical analysis. I also like to find under-$10 stocks with a catalyst, but that's secondary to the chart and volume patterns.

With that in mind, here's a look at several under-$10 stocks that look poised to potentially trade higher from current levels.

Achillion Pharmaceuticals

One under-$10 biopharmaceutical player that's starting to spike within of triggering a big breakout trade is Achillion Pharmaceuticals (ACHN) , which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the U.S. and internationally. This stock has been destroyed by the bears over the last six months, with shares falling sharply by 56.3%.

If you take a glance at the chart for Achillion Pharmaceuticals, you'll notice that this stock recently gapped-down sharply from $6 a share to its new 52-week low of $3.78 a share with monster downside volume flows. Following that move, this stock has now potentially formed a double bottom chart pattern, after shares found some buying interest at $3.78 to $3.91 a share. Shares of Achillion Pharmaceuticals have now started to bounce off that $3.91 low, and it's quickly trending within range of triggering a big breakout trade.

Market players should now look for long-biased trades in shares of Achillion Pharmaceuticals if it manages to break out above some near-term overhead resistance levels at $4.40 to $4.67 a share and then above $4.85 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 2.16 million shares. If that breakout hits soon, then this stock will set up to re-fill some of its previous gap-down-day zone from November that started near $6 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right around those recent double bottom support levels. One can also buy shares of Achillion Pharmaceuticals off strength once it starts to trend above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Adeptus Health

Another under-$10 healthcare player that's starting to trend within range of triggering a near-term breakout trade is Adeptus Health (ADPT) , which owns and operates a network of independent freestanding emergency rooms in the U.S. This stock has been destroyed by the sellers over the last six months, with shares collapsing by 85.6%.

If you take a look at the chart for Adeptus Health, you'll notice that this stock recently formed a double bottom chart pattern, after shares found some buying interest at $7.91 to $7.98 a share over the last month or so. This potential double bottom is coming after shares of Adeptus Health gapped-down sharply lower in November from $30 a share to around $8 a share with heavy downside volume flows. This stock has now started to bounce off those double bottom support levels, and it's beginning to trend within range of triggering a near-term breakout trade.

Market players should now look for long-biased trades in Adeptus Health if it manages to break out above some near-term overhead resistance levels at $8.50 to $8.70 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.26 million shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 20-day moving average of $9.43 a share to $10, or even $10.50 to $11 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right below those recent double bottom support levels. One can also buy shares of Adeptus Health off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Lipocine

One under-$10 specialty pharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Lipocine (LPCN) , which develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. This stock has been smashed lower by the sellers over the last six months, with shares falling sharply by 59.6%.

If you take a glance at the chart for Lipocine, you'll notice that this stock recently formed a double bottom chart pattern, after shares found some buying interest at $3.03 to $3.12 a share over the last month. Following that potential bottom, this stock has now started to uptrend a bit and it's also starting to flirt with its 20-day moving average of $3.59 a share. That move is now quickly pushing shares of Lipocine within range of triggering a near-term breakout trade above some key overhead resistance levels.

Traders should now look for long-biased trades in Lipocine if it manages to break out above both its 20-day moving average of $3.59 a share and its 50-day moving average of $3.74 a share and then above more key resistance levels at $3.80 to $3.90 a share with volume that registers near or above its three-month average action of 525,448 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $4.50 to $5, or even $5.50 a share.

Traders can look to buy this stock off weakness to anticipate that breakout and simply use a stop that sits right around those recent double bottom support levels. One can also buy shares of Lipocine off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Ciber

Another under-$10 technology player that's starting to trend within range of triggering a big breakout trade is Ciber (CBR) , which operates as an information technology (IT) service company worldwide. This stock has been smacked lower by the sellers over the last six months, with shares falling sharply by 47.3%.

If you look at the chart for Ciber, you'll notice that this stock has been uptrending over the last month, with shares moving higher off its low of 63 cents per share to its recent high of 85 cents per share. During that uptrend, shares of Ciber have been making mostly higher lows and higher highs, which is bullish technical price action. That uptrend has now pushed this stock within range of triggering a big breakout trade above some key overhead resistance levels.

Market players should now look for long-biased trades in Ciber if it manages to break out above some near-term overhead resistance levels at 85 cents per share to its 50-day moving average of 91 cents per share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 360,905 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1 to $1.13, or even $1.20 to $1.30 a share.

Traders can look to buy Ciber off weakness to anticipate that breakout and simply use a stop that sits right around some recent double bottom support levels at 77 to 76 cents per share. One can also buy this stock off strength once it starts to bust above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Noodles & Company

One final under-$10 restaurants player that's starting to move within range of triggering a big breakout trade is Noodles & Company  (NDLS - Get Report) , which develops and operates fast casual restaurants in the U.S. This stock has been hit hard by the sellers over the last six months, with shares off sharply by 51.8%.

If you take a glance at the chart for Noodles & Company, you'll notice that this stock has been uptrending over the last month and change, with shares moving higher off its low of $3.51 a share to its recent high of $4.85 a share. During that uptrend, shares of Noodles & Company have been making mostly higher lows and higher highs, which is bullish technical price action. That uptrend has now pushed this stock back above both its 20-day moving average of $4.34 a share and its 50-day moving average of $4.44 a share. Shares of Noodles & Company are now quickly trading within range of triggering a big breakout trade above some key overhead resistance levels.

Traders should now look for long-biased trades in Noodles & Company if it manages to break out above some near-term overhead resistance levels at $4.85 to $5 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 206,855 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $5.40 to $6, or even $6.50 to $7 a share.

Traders can look to buy shares of Noodles & Company off weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support levels at $4.10 to $3.90 a share. One can also buy this stock off strength once it starts to move back above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.